tiprankstipranks
Trending News
More News >

Takeda reports EC approves Adcetris combination for Hodgkin lymphoma

Takeda (TAK) announced that the European Commission approved Adcetris in combination with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone – a chemotherapy regimen – in adult patients with newly diagnosed Stage IIb with risk factors/III/IV Hodgkin lymphoma. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use on April 25, the company noted.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue